Related Experiment Videos
Budesonide in previously untreated autoimmune hepatitis
Johannes Wiegand1, Andreas Schüler, Stephan Kanzler
1Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany.
Summary
Budesonide effectively induced remission in 83.3% of treatment-naïve autoimmune hepatitis patients. This immunosuppressive therapy was well-tolerated, suggesting potential as an alternative treatment for autoimmune hepatitis.
Area of Science:
- Hepatology
- Immunology
- Pharmacology
Background:
- Autoimmune hepatitis (AIH) is a chronic liver disease requiring immunosuppressive therapy.
- Standard treatment (prednisone/azathioprine) can cause significant side effects.
- Novel therapeutic options are needed for AIH induction of remission.
Purpose of the Study:
- To evaluate budesonide's efficacy and tolerability for inducing remission in treatment-naïve AIH patients.
- To assess budesonide as a potential alternative to standard immunosuppressive regimens.
Main Methods:
- An open-label, one-arm, multicenter phase IIa study.
- 12 treatment-naïve AIH patients received budesonide (3 mg thrice daily) for 3 months.
- Remission defined by aspartate aminotransferase and alanine aminotransferase levels < 2x upper limit of normal.
Main Results:
- 83.3% of patients responded to budesonide therapy (58% complete remission, 25% partial response).
- Therapy was well-tolerated in 83.3% of cases.
- Budesonide demonstrated significant efficacy in inducing remission.
Conclusions:
- Budesonide monotherapy is effective and well-tolerated for inducing remission in treatment-naïve AIH.
- Further investigation in controlled trials comparing budesonide to prednisone is warranted.
- Budesonide shows promise as a treatment option for autoimmune hepatitis.